Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study
- 3 February 2018
- journal article
- research article
- Published by Elsevier BV in Contraception
- Vol. 97 (5), 422-427
- https://doi.org/10.1016/j.contraception.2018.01.012
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Oregon Health and Science University
- Health Research
This publication has 18 references indexed in Scilit:
- Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism StudiesEndocrinology, 2016
- Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimensContraception, 2008
- Hormone Therapy and Venous Thromboembolism Among Postmenopausal WomenCirculation, 2007
- New progestagens for contraceptive useHuman Reproduction Update, 2005
- Serum Nestorone® and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen–ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimenContraception, 2005
- Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone® progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimenContraception, 2005
- Ovarian function during use of vaginal rings delivering three different doses of Nestorone®Contraception, 2001
- Nestorone®: a progestin with a unique pharmacological profileSteroids, 2000
- Pharmacokinetics and bioavailability of ST 1435 administered by different routesContraception, 1993
- Comparison of pharmacodynamic properties of various estrogen formulationsAmerican Journal of Obstetrics and Gynecology, 1982